Effects of Testosterone Replacement in Androgen-deficient Women with Hypopituitarism: a Randomized, Double-blind, Placebo-controlled Study
Overview
Authors
Affiliations
Context: Hypopituitarism in women is characterized by profound androgen deficiency due to a loss of adrenal and/or ovarian function. The effects of testosterone replacement in this population have not been reported.
Objective: The objective of the study was to determine whether physiologic testosterone replacement improves bone density, body composition, and/or neurobehavioral function in women with severe androgen deficiency secondary to hypopituitarism.
Design: This was a 12-month randomized, placebo-controlled study.
Setting: The study was conducted at a general clinical research center.
Study Participants: Fifty-one women of reproductive age with androgen deficiency due to hypopituitarism participated.
Intervention: Physiologic testosterone administration using a patch that delivers 300 microg daily or placebo was administered.
Main Outcome Measures: Bone density, fat-free mass, and fat mass were measured by dual x-ray absorptiometry. Thigh muscle and abdominal cross-sectional area were measured by computed tomography scan. Mood, sexual function, quality of life, and cognitive function were assessed using self-administered questionnaires.
Results: Mean free testosterone increased into the normal range during testosterone administration. Mean hip (P = 0.023) and radius (P = 0.007), but not posteroanterior spine, bone mineral density increased in the group receiving testosterone, compared with placebo, as did mean fat-free mass (P = 0.040) and thigh muscle area (P = 0.038), but there was no change in fat mass. Mood (P = 0.029) and sexual function (P = 0.044) improved, as did some aspects of quality of life, but not cognitive function. Testosterone at physiologic replacement levels was well tolerated, with few side effects.
Conclusions: This is the first randomized, double-blind, placebo-controlled study to show a positive effect of testosterone on bone density, body composition, and neurobehavioral function in women with severe androgen deficiency due to hypopituitarism.
Donald D, McDonnell T, OReilly M, Sherlock M Rev Endocr Metab Disord. 2024; 25(5):839-854.
PMID: 39370498 PMC: 11470859. DOI: 10.1007/s11154-024-09897-7.
Metabolic benefits afforded by estradiol and testosterone in both sexes: clinical considerations.
Mauvais-Jarvis F, Lindsey S J Clin Invest. 2024; 134(17).
PMID: 39225098 PMC: 11364390. DOI: 10.1172/JCI180073.
Ilovayskaya I, Zektser V Endocrine. 2024; 85(3):1425-1434.
PMID: 38761348 DOI: 10.1007/s12020-024-03872-7.
Sex Steroid Levels in Women With Hypopituitarism: A Case-controlled Observational Study.
Olivius C, Landin-Wilhelmsen K, Ohlsson C, Poutanen M, Trimpou P, Olsson D J Clin Endocrinol Metab. 2024; 109(11):2967-2978.
PMID: 38570732 PMC: 11479694. DOI: 10.1210/clinem/dgae197.
Androgen deficiency in hypopituitary women: its consequences and management.
Esposito D, Tivesten A, Olivius C, Ragnarsson O, Johannsson G Rev Endocr Metab Disord. 2024; 25(3):479-488.
PMID: 38240912 PMC: 11162366. DOI: 10.1007/s11154-024-09873-1.